Table 5 The detailed resistance rate (%) of Escherichia coli during 2022Q1 to 2023Q2
Antimicrobial | 2022Q1 (n = 63) | 2022Q2 (n = 48) | 2022Q3 (n = 92) | 2022Q4 (n = 75) | 2023Q1 (n = 91) | 2023Q2 (n = 102) |
|---|---|---|---|---|---|---|
Resistance rate (%) | Resistance rate (%) | Resistance rate (%) | Resistance rate (%) | Resistance rate (%) | Resistance rate (%) | |
Amikacin (loanword) | 1.6 | 4.2 | 3.3 | 5.3 | 1.1 | 2 |
Ampicillin (loanword) | 85.7 | 89.6 | 83.7 | 88.2 | 83.5 | 82.4 |
Ampicillin/sulbactam | 39.7 | 29.2 | 30.4 | 26.3 | 23.1 | 13.7 |
Furantoin (antifungal agent) | 0 | 0 | 2.9 | 2.1 | 1.5 | 4.8 |
Cotrimoxazole | 69.8 | 70.8 | 73.9 | 69.7 | 61.5 | 52.9 |
Ciprofloxacin | 54 | 60.4 | 65.2 | 48.7 | 50.5 | 46.1 |
Chloromycetin | 25 | 50 | 45.8 | 34.5 | 25 | 28.2 |
Meropenem (loanword) | 1.6 | 2.1 | 3.3 | 1.3 | 1.1 | 2.9 |
Minocycline (loanword) | 4.8 | 4.2 | 9.8 | 5.3 | 2.2 | 4.9 |
Piperacillin/tazobactam | 12.7 | 6.3 | 4.3 | 1.3 | 2.2 | 3.9 |
Gentamycin (antibiotic) | 34.9 | 39.6 | 47.8 | 44.7 | 39.6 | 33.3 |
Ticarcillin/rodentic acid | 28.6 | 14.6 | 14.1 | 18.4 | 6.6 | 7.8 |
Cefepime | 19 | 20.8 | 30.4 | 31.6 | 26.4 | 25.5 |
Cefuroxime | 41.3 | 41.7 | 51.1 | 57.9 | 44 | 41.2 |
Cefoperazone/sulbactam | 7.9 | 6.3 | 4.3 | 3.9 | 6.6 | 6.9 |
Ceftriaxone | 42.9 | 39.6 | 47.8 | 53.9 | 41.8 | 41.2 |
Ceftazidime (pharmacology) | 27 | 29.2 | 27.2 | 32.9 | 23.1 | 31.4 |
Cefoxitin | 6.3 | 8.3 | 8.7 | 13.2 | 4.4 | 9.8 |
Cefazolin (cephalexin), antifungal agent | 75 | 57.1 | 66.7 | 62.1 | 37.5 | 53.8 |
Imipenem (tylenol) | 1.6 | 2.1 | 3.3 | 0 | 1.1 | 2.9 |
Levofloxacin | 33.3 | 47.9 | 60.9 | 42.1 | 47.3 | 43.1 |